The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Cited by
Sorted by citations
Items 401–500 of 716
Research Progress of Hypertriglyceridemia and Coronary Heart Disease
Ji, Y., & Bai, C. (2018) · Heart and Mind · doi:10.4103/hm.hm_2_19 · Cited by 13
Obesity and Ischemic Heart Disease
McPherson, R. (2015) · Circulation Research · doi:10.1161/circresaha.115.305826 · Cited by 12
Arutyunov, G. P., Boytsov, S. A., Voevoda, M. I., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Shestakova, M. V., Gurevich, V. S., Сергиенко, И. В., Alieva, A. S., et al. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-9-44-51 · Cited by 14
Gruenwald, J., Bongartz, U., Bothe, G., & Uebelhack, R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8378 · Cited by 12
Escudero‐López, B., Cerrillo, I., Ortega, Á., Martı́n, F., & Fernández‐Pachón, M. (2022) · Foods · doi:10.3390/foods11091256 · Cited by 13
Risti, R., Gunn, K. H., Hiis-Hommuk, K., Seeba, N.-N., Karimi, H., Villo, L., Vendelin, M., Neher, S. B., & Lõokene, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283358 · Cited by 12
Gao, F., Ballantyne, C. M., Ma, L., Virani, S. S., Keinan, A., & Brautbar, A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.010 · Cited by 12
Analysis of causal effect of APOA5 variants on premature coronary artery disease
Wang, F., Wang, I. Z., Ellis, S. G., Archacki, S. R., Barnard, J., Hubbard, C. A., Topol, E. J., Chen, Q., & Wang, Q. K. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12273 · Cited by 14
Watts, G. F., & Karpe, F. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.204990rep · Cited by 12
Kim, J. Y., Kim, O. Y., Paik, J. K., Lee, S., & Lee, J. H. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.06.002 · Cited by 11
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 11
Coelho, R. C. L. A., Hermsdorff, H. H. M., Gomide, R. S., Alves, R. D. M., & Bressan, J. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000229 · Cited by 12
Koopal, C., Bemelmans, R. H. H., Marais, A. D., & Visseren, F. L. J. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228199 · Cited by 10
Lowry, D. E., Fenwick, P. H., Roke, K., Jeejeebhoy, K. N., Dhaliwal, R., Brauer, P. M., Royall, D., Tremblay, A., Klein, D., & Mutch, D. M. (2018) · Lifestyle Genomics · doi:10.1159/000494331 · Cited by 13
The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case–Control Study
Hubacek, J. A., Dlouhá, D., Adámková, V., Schwarzová, L., Lánská, V., Češka, R., Satny, M., & Vrablı́k, M. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00412-2 · Cited by 11
Han, H., Dai, D., Wang, W., Zhu, J., Zhu, Z., Lu, L., & Zhang, R. (2019) · Journal of interventional medicine · doi:10.1016/j.jimed.2019.05.005 · Cited by 11
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 12
Hyperlipidemia and cardiovascular disease
Nofer, J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328348a539 · Cited by 11
Holland, D. J., Erne, D., Kostner, K., Leano, R., Haluska, B. A., Marwick, T. H., & Sharman, J. E. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00102.2011 · Cited by 11
Zhao, Y., Sun, S., Liu, J., Zheng, M., Liu, M., Liu, M., & Liu, J. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109831 · Cited by 10
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Mortensen, M. B., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120471 · Cited by 13
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 10
Koohi, F., Khalili, D., Soori, H., Nazemipour, M., & Mansournia, M. A. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100075 · Cited by 11
Hong, S., Kim, K., Han, K., & Park, C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02353-5 · Cited by 10
Brautbar, A., Barbalić, M., Chen, F., Belmont, J. W., Virani, S. S., Scherer, S., Hegele, R. A., & Ballantyne, C. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m034132 · Cited by 10
Khounphinith, E., Yin, R., Cao, X., Huang, F., Wu, J., & Li, H. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.31729 · Cited by 9
Oksala, N., Seppälä, I., Hernesniemi, J. A., Lyytikäinen, L., Kähönen, M. A. P., Mäkelä, K.-M., Reunanen, A., Jula, A., Ala‐Korpela, M., & Lehtimäki, T. J. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.679962 · Cited by 10
Hense, H. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr002 · Cited by 10
Triglyceride-mediated pathways and coronary heart disease
Banerjee, Y., Taranikanti, V., & Bayoumi, R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61447-x · Cited by 10
Laboratory evaluation of lipid parameters in clinical practice
Pancholia, A. K., Kabra, N., & Gupta, R. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.002 · Cited by 14
A potentially underestimated predictor of coronary artery disease risk: The ApoB/ApoA1 ratio
Li, B., Zhao, X., Ding, Y., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32084 · Cited by 11
Ibi, D., Boot, M., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100193 · Cited by 9
Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560 · Cited by 9
Satny, M., Todorovová, V., Altschmiedová, T., Hubacek, J. A., Dlouhá, L., Lánská, V., Soška, V., Kyselák, O., Freiberger, T., Bobák, M., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.11.010 · Cited by 9
Ferreira, C. N., Ferriani, M. D. G. C., Fernandes, A. P., Santos, I. R., Rodrigues, K. F., Lana, Â. M. Q., Almeida, C. R., Loures-Vale, A. A., Gomes, K. B., & Sousa, M. O. (2012) · Gene · doi:10.1016/j.gene.2012.12.016 · Cited by 9
Cui, G., Tian, M., Hu, S., Wang, Y., & Wang, D. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.05.003 · Cited by 10
Osorio-Conles, Ó., Ibarzábal, A., Balibrea, J. M., Vidal, J., Ortega, E., & de Hollanda, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031013 · Cited by 9
Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Watts, G. F., & Karpe, F. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.61 · Cited by 10
Rosenson, R. S., Helenowski, I., & Tangney, C. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6264-6 · Cited by 9
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 9
Arterial function parameters in patients with metabolic syndrome and severe hypertriglyceridemia
Rinkūnienė, E., Butkutė, E., Puronaitė, R., Petrulionienė, Ž., Dzenkeviciute, V., Kasiulevičius, V., & Laucevičius, A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.119 · Cited by 9
2018 George Lyman Duff Memorial Lecture
McPherson, R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311392 · Cited by 11
Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes
Vrablı́k, M., Hubacek, J. A., Dlouhá, D., Šatný, M., Adámková, V., & Češka, R. (2019) · Folia Biologica · doi:10.14712/fb2019065040188 · Cited by 9
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 10
ω-3 carboxylic acids for hypertriglyceridemia
Roth, E. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.991307 · Cited by 8
Song, K. H., Park, A.-Y., Kim, J., & Yeul, J. (2013) · BioMed Research International · doi:10.1155/2013/892491 · Cited by 8
Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 9
Changes in adiposity modulate the APOA5 genetic effect on blood lipids: A longitudinal cohort study
Lin, H., Xuan, L., Xiang, J., Hou, Y., Dai, H., Wang, T., Zhao, Z., Wang, S., Lu, J., Xu, Y., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.031 · Cited by 9
Evans, D., Aberle, J., & Beil, F.-U. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.53 · Cited by 8
Okada, K., Furusyo, N., Murata, M., Sawayama, Y., Kainuma, M., & Hayashi, J. (2012) · Endocrine · doi:10.1007/s12020-011-9532-8 · Cited by 8
Common variants associated with blood lipid levels do not affect carotid plaque composition
Siemelink, M. A., van der Laan, S. W., van Setten, J., de Vries, J. P. P. M., de Borst, G. J., Moll, F. L., den Ruijter, H. M., Asselbergs, F. W., Pasterkamp, G., & de Bakker, P. I. W. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.041 · Cited by 8
Christie, S., Robiou-du-Pont, S., Anand, S. S., Morrison, K. M., McDonald, S. D., Paré, G., Atkinson, S. A., Teo, K. K., & Meyre, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-00102-1 · Cited by 8
Picard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8
Hubacek, J. A., Peasey, A., Kubínová, R., Pikhart, H., & Bobák, M. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.08.008 · Cited by 8
Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
Mayr, M., Gerszten, R. E., & Kiechl, S. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.040 · Cited by 9
Association of Ratio of Apolipoprotein B to Apolipoprotein A1 With Survival in Peritoneal Dialysis
Yu, J., Xia, X., Huang, N., Qiu, Y., Yang, X., Mao, H., Chen, W., & Huang, F. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.801979 · Cited by 7
Gálos, G., Rábai, M., Szabó, R., Szalai, R., Tóth, K., Hegyi, P., & Sándor, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27954 · Cited by 7
Ko, Y.-S., Hsu, L., Wu, S., Liao, M.-S., Teng, M., Chou, H., & Ko, Y. (2025) · Genes · doi:10.3390/genes16020157 · Cited by 8
Nosal, B. M., Sakaki, J. R., Mofrad, M. D., Macdonald, Z., Mahoney, K. J., Thornton, S., Patel, D., Drossman, J., Lee, E. C., & Chun, O. K. (2023) · Biomedicines · doi:10.3390/biomedicines11102834 · Cited by 7
Kataoka, Y., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., Tamanaha, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.03.001 · Cited by 7
Kenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 8
Jeff, J. M., Peloso, G. M., & Do, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000277 · Cited by 7
Sümegi, K., Duga, B., Melegh, B., Bánfai, Z., Kövesdi, E., Maász, A., & Melegh, B. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0197-3 · Cited by 7
Hallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Dyslipidemia: Current Perspectives and Implications for Clinical Practice
Majanović, S. K., Cvijanović, O., Detel, D., Jovanović, G. K., Bakula, M., Rahelić, D., Čaljkušić‐Mance, T., Šoić-Vranić, T., & Cvek, S. Z. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98386 · Cited by 9
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7
Sex differences in the non-linear association between BMI and LDL cholesterol in type 2 diabetes
Li, K., Cao, B., Wang, X., Chai, T., Ke, J., & Zhao, D. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1180012 · Cited by 7
Lean body mass, not FFA, predicts VLDL-TG secretion rate in healthy men
Søndergaard, E., Nellemann, B., Sørensen, L. P., Christensen, B., Gormsen, L. C., & Nielsen, S. (2015) · Obesity · doi:10.1002/oby.21108 · Cited by 7
Apolipoprotein C-II Deficiency with No Rare Variant in the APOC2 Gene
Takase, S., Osuga, J.-I., Fujita, H., Hara, K., Sekiya, M., Igarashi, M., Takanashi, M., Takeuchi, Y., Izumida, Y., Ohta, K., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.16592 · Cited by 7
Application of Genome-Wide Association Studies in Coronary Artery Disease
Zheng, H., Zeng, Z., Wen, H., Wang, P., Huang, C., Huang, P., Chen, Q., Gong, D., & Qiu, X. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105125148 · Cited by 7
Kim, M., Yoo, H. J., Lee, H. J., & Lee, J. H. (2018) · Hypertension Research · doi:10.1038/s41440-018-0137-y · Cited by 7
Peng, X., Lian, Z., O’Brien, V., Xiao, J., Litchfield, B., Perrard, X. D., Lu, X., Ni, J., Mukherjee, A., Simmons, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100763 · Cited by 7
Lipid Profile and Management of Dyslipidemias in Pregnancy
Kosmas, C. E., Rallidis, L. S., Hoursalas, I. S., Zoumi, E.-A., & Kostara, C. E. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12110445 · Cited by 9
Sun, D., Sun, L. L., Xu, Q., Wang, H., Yang, J., & Yuan, Y. (2017) · Medical Science Monitor · doi:10.12659/msm.899587 · Cited by 6
Kim, J. D., Hwang, Y., Ahn, H. Y., & Park, C. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.5.975 · Cited by 6
Verbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 6
Liu, H., Xie, H., Li, C., Wang, L., Chen, Q., Ouyang, X., & Yan, C. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00715 · Cited by 6
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?
Arsenault, B. J., Després, J., & Boekholdt, S. M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.51 · Cited by 6
Valdivielso, P., Mostaza, J. M., Jarauta, E., Lahoz, C., Aranda, J. L., de Aranzubía, P. S., Argimón-Pallás, J., Carrasco-Miras, F., Civeira, F., & Ascaso, J. F. (2013) · Clinical Lipidology · doi:10.2217/clp.13.56 · Cited by 6
Lipids: a personal view of the past decade
Katsiki, N., & Mikhailidis, D. P. (2018) · HORMONES · doi:10.1007/s42000-018-0058-9 · Cited by 6
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Triglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Genetic determination of triglyceridemia with special focus on apolipoprotein gene variants
Vrablı́k, M., & Hubacek, J. A. (2010) · Clinical Lipidology · doi:10.2217/clp.10.38 · Cited by 6
Watts, G. F. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283404fb5 · Cited by 6
Gordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.11.377747 · Cited by 6
Bleich, D., Biggs, M. L., Gardin, J. M., Lyles, M. F., Siscovick, D. S., & Mukamal, K. J. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100725 · Cited by 5
Triglycerides and T Cells in Cardiovascular Risk
Reilly, N. A., Mulder, J. W. C. M., Dekkers, K. F., Kuipers, T. B., der Zee, L. C. V. V., Mulder, M. T., van Lennep, J. E. R., Jukema, J. W., & Heijmans, B. T. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101359 · Cited by 5
Lou, Z., Han, L., Qu, Y., Zhou, A., He, Y., Yan, M., Cheng, B., Liu, M., Jiang, T., & Huang, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2409248 · Cited by 5
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2511 · Cited by 5
The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: An update
Dabravolski, S. A., Churov, A. V., Sukhorukov, V. N., Kovyanova, T. I., Beloyartsev, D. F., Lyapina, I. N., & Orekhov, A. N. (2024) · SAGE Open Medicine · doi:10.1177/20503121241289828 · Cited by 4
Köenig, W., Marx, N., Thiery, J., & Klose, G. (2012) · Der Kardiologe · doi:10.1007/s12181-012-0420-0 · Cited by 5
Chukwurah, M. I., & Miller, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01926-2 · Cited by 5
Archakov, А., Kukharchuk, V. V., Lisitsa, A., Ponomarenko, E. A., Romashova, Y. A., Pleshakova, T. O., Yarovaya, E. B., Kutsenko, V. A., Guseva, M., Beregovykh, V. V., et al. (2024) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_274_23 · Cited by 5
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
